open access

Vol 7, No 4 (2010)
Review paper
Published online: 2010-09-13
Get Citation

Child and adolescent schizophrenia - biological background for diagnosis and treatment

Aleksandra Rajewska-Rager, Andrzej Rajewski
Psychiatria 2010;7(4):161-167.

open access

Vol 7, No 4 (2010)
Prace poglądowe - nadesłane
Published online: 2010-09-13

Abstract

Diagnosing and treatment of children’s schizophrenia (COS) and early onset schizophrenia (EOS) is often challenging due to lack of diagnostical and therapeutical criteria and considerable comorbidity. The growing number of neuroimaging data indicate a presence of many structural brain abnormalities that may confirm neurodevelopmental hypothesis of schizophrenia. We still couldn’t find any of biological markers which would allow to determine vulnerability for schizophrenia in child and adolescancy period. The markers that are considered, belong to the wide group of neuropsychological, neurophisiological and other functional brain disturbances. The treatment of COS and EOS is based on the same rules as these used in the adult schizophrenia treatment. Atypical neuroleptics are considered as the most safe treatment for children and adolescent suffering from schizophrenia.
Psychiatry 2010; 7, 4: 161-167

Abstract

Diagnosing and treatment of children’s schizophrenia (COS) and early onset schizophrenia (EOS) is often challenging due to lack of diagnostical and therapeutical criteria and considerable comorbidity. The growing number of neuroimaging data indicate a presence of many structural brain abnormalities that may confirm neurodevelopmental hypothesis of schizophrenia. We still couldn’t find any of biological markers which would allow to determine vulnerability for schizophrenia in child and adolescancy period. The markers that are considered, belong to the wide group of neuropsychological, neurophisiological and other functional brain disturbances. The treatment of COS and EOS is based on the same rules as these used in the adult schizophrenia treatment. Atypical neuroleptics are considered as the most safe treatment for children and adolescent suffering from schizophrenia.
Psychiatry 2010; 7, 4: 161-167
Get Citation

Keywords

early and very early onset of schizophrenia; neuroimaging studies; pharmacotherapy

About this article
Title

Child and adolescent schizophrenia - biological background for diagnosis and treatment

Journal

Psychiatria (Psychiatry)

Issue

Vol 7, No 4 (2010)

Article type

Review paper

Pages

161-167

Published online

2010-09-13

Bibliographic record

Psychiatria 2010;7(4):161-167.

Keywords

early and very early onset of schizophrenia
neuroimaging studies
pharmacotherapy

Authors

Aleksandra Rajewska-Rager
Andrzej Rajewski

References (42)
  1. Masi G, Pfanner C, Mucci M, et al. Children with schizophrenia: clinical picture and pharmacological treatment. CNS Drugs. 2006; 20(10): 841–866.
  2. Shioiri T, Shinada K, Kuwabara H, et al. Early prodromal symptoms and diagnoses before first psychotic episode in 219 inpatients with schizophrenia. Psychiatry Clin Neurosci. 2007; 61(4): 348–354.
  3. Remschmidt H. Early-onset schizophrenia as a progressive-deteriorating developmental disorder: evidence from child psychiatry. J Neural Transm (Vienna). 2002; 109(1): 101–117.
  4. Selten JP, Veen ND, Hoek HW, et al. Early course of schizophrenia in a representative Dutch incidence cohort. Schizophr Res. 2007; 97(1-3): 79–87.
  5. Nicolson R, Lenane M, Singaracharlu S, et al. Premorbid speech and language impairments in childhood-onset schizophrenia: association with risk factors. Am J Psychiatry. 2000; 157(5): 794–800.
  6. Rabinowitz J, Levine SZ, Häfner H. A population based elaboration of the role of age of onset on the course of schizophrenia. Schizophr Res. 2006; 88(1-3): 96–101.
  7. Fraguas D, de Castro MJ, Medina O, et al. Does diagnostic classification of early-onset psychosis change over follow-up? Child Psychiatry Hum Dev. 2008; 39(2): 137–145.
  8. Nicolson R, Brookner FB, Lenane M, et al. Parental schizophrenia spectrum disorders in childhood-onset and adult-onset schizophrenia. Am J Psychiatry. 2003; 160(3): 490–495.
  9. Di Forti M, Morgan C, Dazzan P, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry. 2009; 195(6): 488–491.
  10. Chance SA, Casanova MF, Switala AE, et al. A review of MRI findings in schizophrenia. Schizophr Res. 2001; 49(1-2): 1–52.
  11. Douaud G, Mackay C, Andersson J, et al. Schizophrenia delays and alters maturation of the brain in adolescence. Brain. 2009; 132(Pt 9): 2437–2448.
  12. Sowell ER, Levitt J, Thompson PM, et al. Brain abnormalities in early-onset schizophrenia spectrum disorder observed with statistical parametric mapping of structural magnetic resonance images. Am J Psychiatry. 2000; 157(9): 1475–1484.
  13. Janssen J, Reig S, Parellada M, et al. Regional gray matter volume deficits in adolescents with first-episode psychosis. J Am Acad Child Adolesc Psychiatry. 2008; 47(11): 1311–1320.
  14. Pagsberg AK, Baaré WFC, Raabjerg Christensen AM, et al. Structural brain abnormalities in early onset first-episode psychosis. J Neural Transm (Vienna). 2007; 114(4): 489–498.
  15. Nugent TF, Herman DH, Ordonez A, et al. Dynamic mapping of hippocampal development in childhood onset schizophrenia. Schizophr Res. 2007; 90(1-3): 62–70.
  16. Arango C, Moreno C, Martínez S, et al. Longitudinal brain changes in early-onset psychosis. Schizophr Bull. 2008; 34(2): 341–353.
  17. Brans RGH, van Haren NEM, van Baal GC, et al. Heritability of changes in brain volume over time in twin pairs discordant for schizophrenia. Arch Gen Psychiatry. 2008; 65(11): 1259–1268.
  18. Ashtari M, Cervellione KL, Hasan KM, et al. White matter development during late adolescence in healthy males: a cross-sectional diffusion tensor imaging study. Neuroimage. 2007; 35(2): 501–510.
  19. White T, Cullen K, Rohrer LM, et al. Limbic structures and networks in children and adolescents with schizophrenia. Schizophr Bull. 2008; 34(1): 18–29.
  20. Douaud G, Smith S, Jenkinson M, et al. Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia. Brain. 2007; 130(Pt 9): 2375–2386.
  21. Kyriakopoulos M, Vyas NS, Barker GJ, et al. A diffusion tensor imaging study of white matter in early-onset schizophrenia. Biol Psychiatry. 2008; 63(5): 519–523.
  22. Kumra S, Ashtari M, McMeniman M, et al. Reduced frontal white matter integrity in early-onset schizophrenia: a preliminary study. Biol Psychiatry. 2004; 55(12): 1138–1145.
  23. White T, Kendi AT, Lehéricy S, et al. Disruption of hippocampal connectivity in children and adolescents with schizophrenia--a voxel-based diffusion tensor imaging study. Schizophr Res. 2007; 90(1-3): 302–307.
  24. O'Neill J, Levitt J, Caplan R, et al. 1H MRSI evidence of metabolic abnormalities in childhood-onset schizophrenia. Neuroimage. 2004; 21(4): 1781–1789.
  25. Stanley JA, Vemulapalli M, Nutche J, et al. Reduced N-acetyl-aspartate levels in schizophrenia patients with a younger onset age: a single-voxel 1H spectroscopy study. Schizophr Res. 2007; 93(1-3): 23–32.
  26. Kumra S, Sporn A, Hommer DW, et al. Smooth pursuit eye-tracking impairment in childhood-onset psychotic disorders. Am J Psychiatry. 2001; 158(8): 1291–1298.
  27. Sporn A, Greenstein D, Gogtay N, et al. Childhood-onset schizophrenia: smooth pursuit eye-tracking dysfunction in family members. Schizophr Res. 2005; 73(2-3): 243–252.
  28. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000; 157(4): 549–559.
  29. Gochman PA, Greenstein D, Sporn A, et al. IQ stabilization in childhood-onset schizophrenia. Schizophr Res. 2005; 77(2-3): 271–277.
  30. Frangou S, Hadjulis M, Vourdas A. The Maudsley early onset schizophrenia study: cognitive function over a 4-year follow-up period. Schizophr Bull. 2008; 34(1): 52–59.
  31. Varnäs K, Lawyer G, Jönsson EG, et al. Brain-derived neurotrophic factor polymorphisms and frontal cortex morphology in schizophrenia. Psychiatr Genet. 2008; 18(4): 177–183.
  32. Mata I, Perez-Iglesias R, Roiz-Santiañez R, et al. A neuregulin 1 variant is associated with increased lateral ventricle volume in patients with first-episode schizophrenia. Biol Psychiatry. 2009; 65(6): 535–540.
  33. Potkin SG, Turner JA, Guffanti G, et al. Genome-wide strategies for discovering genetic influences on cognition and cognitive disorders: methodological considerations. Cogn Neuropsychiatry. 2009; 14(4-5): 391–418.
  34. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996; 53(12): 1090–1097.
  35. Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2004; 29(1): 133–145.
  36. Kranzler H, Roofeh D, Gerbino-Rosen G, et al. Clozapine: its impact on aggressive behavior among children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2005; 44(1): 55–63.
  37. Haas M, Unis AS, Armenteros J, et al. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol. 2009; 19(6): 611–621.
  38. Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006; 63(7): 721–730.
  39. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. J Child Adolesc Psychopharmacol. 2008; 18(4): 307–316.
  40. Haas M, Eerdekens M, Kushner S, et al. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry. 2009; 194(2): 158–164.
  41. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008; 165(11): 1420–1431.
  42. Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008; 165(11): 1432–1441.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl